Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Approval of a Darzalex Faspro therapy combo is sought in Europe

Johnson & Johnson has applied to the European Medicines Agency (EMA) for approval of its under-the-skin formulation of Darzalex (daratumumab), called Darzalex Faspro (daratumumab and hyaluronidase-fihj), in combination with a standard triple-therapy regimen for treating adults with newly diagnosed multiple myeloma who are eligible for…

Blenrep delays disease progression by nearly 3X versus Darzalex

GlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by more than half the risk of disease progression or death in people with relapsed or refractory multiple myeloma (RRMM) relative to Darzalex (daratumumab). A nearly three times greater delay in disease progression and a 43% lower risk of death was associated…

Obesity, smoking, and poor sleep raise risk of myeloma precursor

Obesity, a history of heavy smoking, and limited sleep are risk factors for developing monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to multiple myeloma, a large U.S. study shows. These findings will help inform future work to identify groups who “may benefit from targeted screening strategies, enhanced…

Survival rates by race found similar with Abecma in myeloma study

Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but overall survival rates were similar between hard-to-treat Black, Hispanic, and white patients, a new U.S. study found. “We see that Black and white patients with multiple…

International Myeloma Foundation Wins 2022 AWS IMAGINE Grant

The International Myeloma Foundation (IMF) is one of the nonprofit organizations awarded the 2022 Amazon Web Services (AWS) IMAGINE Grant, which was established to help harness technology for patients’ needs. IMF was a winner in the Momentum to Modernize category, wherein its efforts to use cloud technology to educate…